ECMO support is an established life saving therapy for potentially reversible respiratory and/or cardiac failure. Improvement
of outcome depends on effective treatment of the primary diagnosis and complications. Adequate drug therapy is important in reaching
these goals. Pharmacokinetic and pharmacodynamic data in neonates and older children on ECMO are sparse. Most studies show altered
volume of distribution and clearance for the drugs studied. This article gives an overview of the available PK and PD studies in neonates
and children on ECMO, suggests possible mechanisms of altered PK and PD and identifies areas of interest for further research.
Keywords: Neonate, child, extracorporeal membrane oxygenation, sedation, analgesia, pharmacology, pharmacokinetics, pharmacodynamics, diagnoses, infections
Rights & PermissionsPrintExport